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In the last decades, the chemical synthesis of short oligonucleotides has become 
an important aspect of study due to the discovery of new functions for nucleic acids 
such as antisense oligonucleotides (ASOs), aptamers, DNAzymes, microRNA 
(miRNA) and small interfering RNA (siRNA). The applications in modern 
therapies and fundamental medicine on the treatment of different cancer diseases, 
viral infections and genetic disorders has established the necessity to develop 
scalable methods for their cheaper and easier industrial manufacture. While small 
scale solid-phase oligonucleotide synthesis is the method of choice in the field, 
various challenges still remain associated with the production of short DNA and 
RNA-oligomers in very large quantities. On the other hand, solution phase 
synthesis of oligonucleotides offers a more predictable scaling-up of the synthesis 
and is amenable to standard industrial manufacture techniques. 
In the present thesis, various protocols for the synthesis of short DNA and RNA 
oligomers have been studied on a peracetylated and methylated β-cyclodextrin, and also 
on a pentaerythritol-derived support. On using the peracetylated and methylated β-
cyclodextrin soluble supports, the coupling cycle was simplified by replacement of 
the typical 5′-O-(4,4′-dimethoxytrityl) protecting group with an acid-labile acetal-
protected 5′-O-(1-methoxy-1-methylethyl) group, which upon acid-catalyzed 
methanolysis released easily removable volatile products. For this reason monomeric 
building blocks 5′-O-(1-methoxy-1-methylethyl) 3′-(2-cyano-ethyl-N,N-
diisopropylphosphoramidite) were synthesized. Alternatively, on using the 
precipitative pentaerythritol support, novel 2´-O-(2-cyanoethyl)-5´-O-(1-methoxy-1-
methylethyl) protected phosphoramidite building blocks for RNA synthesis have been 
prepared and their applicability by the synthesis of a pentamer was demonstrated. 
Similarly, a method for the preparation of short RNAs from commercially available 
5´-O-(4,4´-dimethoxytrityl)-2´-O-(tert-butyldimethyl-silyl)ribonucleoside 3´-(2-
cyanoethyl-N,N-diisopropylphosphoramidite) building blocks has been developed.  
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Ac             acetyl 
ACE         bis(2-acetoxyethoxy)methyl 
Ade                adenine 
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DMAc  N,N-dimethylacetamide 
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DMSO  dimethylsulfoxide 
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ESI-MS  electrospray ionization mass spectrometry 
Et   ethyl 
ETT   5-ethylthio-1H-tetrazole 
FDA   Food and Drug Administration 
Gua   guanine 
HELP  High Efficiency Liquid Phase 
HPLC  high-performance liquid chromatography 
HPX   hexakis(p-hydroxyphenyl)xylene 
HRMS  high resolution mass spectrometry 
ibu   isobutyryl 
10  Abbreviations   
 
IEHPLC  ion exchange high-performance liquid chromatography 
Im   imidazole 
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miRNA  microRNA 
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SELEX  systematic evolution of ligands by exponential enrichment 
siRNA  small interfering ribonucleic acid 
SPS   solid-phase synthesis 
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TBAF  tetrabutylammonium fluoride 
TBAI   tetrabutylammonium iodide 
TBDMS  tert-butyldimethylsilyl 
t-Bu   tert-butyl 
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While the central role of nucleic acids in storage, transmission and dissemination 
of genetic information has been known since the middle of the twentieth century, 
the interest in nucleic acids as drugs and drug targets dates back only to the 
begining of 1980s. Zamecnik & Stephenson1 (1978) found that Rous Sarcoma 
virus replication may be inhibited by a specific oligonucleotide. This pioneering 
work brought up the question: could oligonucleotides also be used as drugs to 
combat against tumors, viral and hereditary diseases?  Contrary to the “classical” 
drug treatment concept, the underlying idea of these antisense drugs (Figure 1) is 
that arresting of mRNA selectively prevents the transfer of information from DNA 
to ribosomes and, hence, stops the protein synthesis. In theory, any mRNA may be 
entirely selectively arrested by a complementary 17-mer oligonucleotide2.  
 
Figure 1. The underlying principle of selective inhibition of protein synthesis by antisense 
oligonucleotides (ASOs) and the “classical” drug treatment. 
More recently splice switching oligos (SSOs) have been used for targeting of 
various disease-related genes3. The concept of SSOs is simple: chemically 
modified oligonucleotides block the access of the spliceosome to a splice site in 
the targeted pre-mRNA, producing the redirection of the process to another 
pathway (Figure 2). The modulation of the pre-mRNA via the SSOs has important 
therapeutic values, since it may be used to correct defective pre-mRNA and restore 
the translation when a reading frame is re-established by exon skipping and also 
to encode novel proteins with beneficial properties4. Splice switching oligos 




Figure 2. Exon skipping, an example of the action of splice-switching oligo-nucleotides (SSOs). 
The exclusion of a particular exon is carried out in the presence of complementary SSOs. 
In late 1990s, the phenomenon of RNA interference (RNAi) had an important 
impact in the field of cell biology when Fire et al5. discovered that double stranded 
RNA (dsRNA) could efficienty inhibit gene expression. Afterward, the interest of 
oligonucleotide-based therapeutic technologies gradually shifted to RNA-
oligonucleotides. Small interfering RNAs (siRNA)6 that form the basis of RNAi-
therapy, are 21 nucleotides long dsRNAs with 2 nucleotide long overhangs. 
siRNAs can modulate the gene expression to eliminate a gene-related disease7 by 
first loading the antisense strand into the RISC (RNA-induced silencing complex) 
protein complex and inducing the enzymatic degradation upon binding to the target 
mRNA (Figure 3).  
Another mode of RNAi-based therapy uses endogenous microRNA (miRNA)8 as 
targets of antisense oligonucleotides (called now antagomirs). miRNAs are 
processed by the same enzyme system (RISC complex) as siRNAs and they, hence, 




Figure 3. Model involving RNAi (siRNA and miRNA) principle. 
Besides the therapies discussed above, Tuerk and Gold9 in 1990s developed a 
technique called SELEX (Systematic Evolution of Ligands by EXponential 
Enrichment) for the isolation of synthetic oligonucleotides known as aptamers. 
Contrary to the previous therapeutic approaches in which the target was a mRNA 
molecule, aptamers are short single stranded oligonucleotides that form 3D 
structures with the capacity of binding to a ligand target by non-covalent bonds. In 
other words, they are able to form stable complexes with non-nucleic acid targets 
(Figure 4). High affinity and specificity together with low toxicity and 
immunogeneicity are the main advantages of these therapeutic agents.  A special 
subtype of aptamers are spiegelmers10-11 that offers good resistance to nucleases 
and, hence, excellent stability from degradation. They are composed of unnatural 
L-nucleosides and the recognition of the targets takes place as with the other 
aptamers.  
 




Over the last two decades, the importance of nucleic acids as drug targets and 
oligonucleotides as drugs has considerably expanded due to the promises that they 
have shown on treatment of different cancer diseases, viral infections and genetic 
disorders12. As of year 2015, two antisense oligonucleotides named Vitravene13 
and Kynamro14 (21-mer and 20-mer oligos, respectively) have been approved by 
the FDA for clinical use and several antisense drug candidates are in phase III 
clinical trials15. Similarly, one aptamer named Macugen16 (28-mer 
oligonucleotide) has received approval by the FDA for the treatment of macular 
degenerations. In addition, more than hundred oligonucleotide drug candidates are 
currently undergoing clinical trials of various phases17 and it is expected that some 
of them will soon be approved for pharmaceutical commercialization. As a proof 
of concept, one SSO is in phase III clinical trial and two are in phase II15. Also 
several siRNA drug candidates are in phase II clinical trials18 and one antagomir 
is in phase II15. 
Apart from these potential forms of chemotherapy, another aspect to be considered 
is the use of oligonucleotides as raw materials for the construction of nano scale 
objects and devices. By using oligonucleotides, different nanostructured materials 
have been assembled for medical and computational applications19. 
Nanomechanical devices based on structural transitions induced by sequence 
dependent interactions have already been realized at a proof of concept level. 
Although the field has rapidly expanded in the last decade, the study of 
oligonucleotide-based nanotechnology still is at the early stage and significant 
progress will soon provide novel materials with different applications. 
The synthesis of large amounts of oligonucleotide-based drugs is fundamental for 
their development as potential therapeutic agents and as starting material for 
various nano-scale constructs. The increased demand of larger quantities of 
oligonucleotides for these purposes has urged the need for novel large scale 
production platforms of oligonucleotides20.  
The current mainstream platform for the manufacture of ONs is the well-known 
solid phase synthesis. It is the method of choice for the small scale assembly of 
oligonucleotides and for more than 10 years has been routinely practiced on a 
higher scale21-22. Although the actual manufacture of oligonucleotides on an 
automated synthesizer is fast and efficient, the synthesis scale still is limited. The 
synthesis platforms available do not allow production in multikilogram quantities 
per batch23. The development of new methodologies and strategies for scaling-up 




1.1 DNA and RNA structures 
Both DNA and RNA are composed of three main constituents: a nitrogenous base, 
a pentose sugar and a phosphate group. The nitrogenous base is either a purine 
base [adenine (Ade) or guanine (Gua)] or a pyrimidine base [thymine (Thy), uracil 
(Ura) or cytosine (Cyt)] (Scheme 1). The N1 of pyrimidine base or N9 of purine 
base is bound to the C1 position of the pentose by a β-glycosyl linkage, and the 
resulting nucleosides form a linear polymer by 3’,5’-phosphodiester bonds. There 
are only two differences in the structure of DNA and RNA oligonucleotides: 1) 
DNA cotains a 2-deoxyribose sugar whereas RNA is composed of a ribose sugar, 
and 2) RNA nucleosides have uracil bases instead of thymine bases (DNA). 
 
Scheme 1. Purine and pyrimidine bases, and general structure of single-stranded DNA and RNA.  
1.2 General remarks of oligonucleotide synthesis 
The chemical synthesis of oligonucleotides usually takes place in the 3’→5’ 
direction. It is carried out in a stepwise manner by linking monomeric building 
blocks in a predesign order to the growing chain by phosphodiester bonds. The 
procedures utilized nowadays for the synthesis of these polymers are based on the 
use of a solid support and the so-called phosphoramidite chemistry. This approach 
utilizes the P(III) oxidation state instead of the P(V) state during the coupling step, 
because of its higher reactivity25. Accordingly, short coupling time and high 
coupling efficiency have been achieved. In fact, as shown in Figure 1, a high 
stepwise coupling yield is needed in order to obtain an acceptable overall yield, 
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because of the exponential dependence of the overall yield on the number of 
coupling steps26. 
 
Figure 1. Overall yield vs number of steps coupling yield at different stepwise coupling yields26.  
1.3 Solid Phase Synthesis. 
The general solid-phase synthesis (SPS) strategy is simple: the 3´-terminal 
nucleoside is bound to an insoluble polymer or silica support on which the chain 
assembly takes place. After each coupling, impurities and excess of reagents are 
washed away. The process is repeated as many times as the desired product is 
accomplished and finally the oligonucleotide is released from the solid support 

























Scheme 2. General oligonucleotide solid-phase synthesis strategy. PG stands for the commonly 
used acid labile 4,4´-dimethoxytrityl (DMTr) protecting group; (i) coupling, oxidation and 
capping; (ii) removal of the 5´-O-protecting group; (iii) cleavage of the fabricated oligonucleotide 
from the solid support. 
There are many attributes regarding the dominance of SPS of oligonucleotides. 
The first and most important benefit is that the use of a solid support [generally 
Controlled Pore Glass (CPG), insoluble polymer or silica] allows the removal of 
excess reagents and impurities by simple washing after every step. In addition, a 
single automated synthesizer can do nearly any oligonucleotide by the standard 
phosphoramidite chemistry in a really fast and reproducible manner, eliminating 
any human error during the production.   
The mechanization and automation of the solid-phase synthesizers is based on 
packing the solid-support into a small column and making the reagents to pass 
through it. This methodology allows the synthesis of oligonucleotides inside the 
column while the unreacted excess reagents and building blocks are washed out to 
the waste. Both DNA and RNA solid-phase synthesizers using phosphoramidite 
chemistry extend the chain one nucleotide at a time by a four step coupling cycle 
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including the 5’-terminus deprotection of the solid-supported chain, coupling of 
the next building block, capping of unreacted chains and oxidation of the phosphite 
diester linkage obtained to a phosphate triester (Figure 2). 
 
Figure 2. Oligonucleotide synthetic cycle. These 4 steps are repeated as many times as required 
for the synthesis of the desired oligonucleotide25. PG stands for protecting group and Ce stands 
for 2-cyanoethyl protection. 
1.4 Phosphoramidite coupling activators 
An activator is needed to enable the coupling, i. e. the nucleophilic displacement 
of the dialkylamino group of the nucleoside 3´-(O-alkyl-N,N-dialkyl-
phosphoramidite) with the 5´-OH of the support anchored chain   (Scheme 3). The 
role of the activator is dual: to protonate the dialkylated amino group of the 
phosphoramidite and to act as a nucleophile that displaces it.  In more detail, 
nucleophilic attack of the activator on phosphorus tends to elongate the P-NR2 
bond, which increases the electron density at the departing nitrogen, leading to its 
protonation and eventually departure of dialkylamine as a neutral species25,27,28. 
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Finally, the phosphorus bound activator becomes, as a good leaving group, 
displaced by the 5’-hydroxyl group. The unstable phosphite triester is later 
oxidized to phosphate triester with aqueous iodine. 
 
Scheme 3. Mechanism of activation, coupling and oxidation of the phosphor-amidite chemistry.  
The first activator reported29 for phosphoramidite coupling was 1-H-tetrazole, 
which still continues to be one of the most extensively used activators. Its acidic 
strength (pKa = 4.8) indicates that it is a reasonably efficient proton donor, but 
leaves still 4,4´-dimethoxytrityl group (DMTr), the most extensively used acid 
labile protecting group for the 5´-OH, untouched.  Slightly more acidic tetrazole-
derived activators have more recently been developed by modifying the C5 
position. Figure 3 represents a few examples of common activators. All of them 
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are azoles, including modified tetrazoles, such as ETT (pKa = 4.28) and BTT (pKa 
= 4.08), and less acidic but more nucleophilic DCI (pKa = 5.2)30. 
 
 
Figure 3. Examples of coupling activators commonly used in the phosphor-amidite chemistry. 
 
1.5 Protecting groups 
1.5.1 Base protecting groups 
The utilization of appropriate protecting groups (PGs) in oligonucleotide synthesis 
is crucial. The standard oligonucleotide protecting groups still widely used were 
developed by Khorana and co-workers31,32,33,34. In spite of the rather harsh 
hydrolytic conditions needed for their deprotection, exocyclic amines of the base 
moieties are usually protected with an isobutyryl (for guanosine) and benzoyl or 
acetyl groups (for adenosine and cytidine)(Figure 4). The reason behind these 
choices is the stability of these groups under neutral and slightly acidic conditions. 
However, somewhat more base labile dimethylaminomethylene or much more 
labile phenoxyacetyl or 4-(tert-butyl)phenoxyacetyl groups may be used when 
milder conditions for the exocyclic deprotection step are for some reason needed. 
Thymidine and uridine are not usually protected.  In general, once the synthesis of 
the intended oligonucleotide chain is completed, the final deprotection of N-acyl 
groups of DNA is usually performed by treatment with concentrated aqueous 
ammonia. For the deprotection of RNA, somewhat milder treatment with ethanolic 
ammonia is usually preferred or pressurized ammonia gas is used. 
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Figure 4. Standard exocyclic amino group protections. 
1.5.2 DNA and RNA 5’-OH protection 
The sugar moiety 5’-hydroxyl group is usually protected by the traditional acid-
labile 4,4’-dimethoxytrityl (DMTr) protecting group. One of the attributes 
regarding its dominance is the stable carbocation formed upon the acidolytic 
removal. The characteristic orange color of the carbocation allows quantification 
of the stepwise yield of the synthesis.  
1.5.3 RNA 2’-O-protection 
Contrarily to the predominance of the 5´-O-DMTr protection, a wide selection of 
protecting groups has been investigated over the past years for the 2’-O-protection 
of ribonucleosides. As a general requirement, the 2’-hydroxyl protecting group 
should not retard the coupling reaction and, hence, bulky groups should be 
avoided.  In addition, the protection should withstand the acidic conditions used 
for removal of 5´-O-DMTr group and the basic conditions required for removal of 
the phosphate protecting group, since 2´-OH attacks extremely rapidly on 
protected phosphate group35,36. The most popular among the 2´-O-protecting 
groups is the fluoride ion labile tert-butyldimethylsilyl (TBDMS) group.37 The 
wide range of alternatives includes bis(2-acetoxyethoxy)methyl (ACE)38, tert-
butyldithiomethyl (DTM)39, [(2-nitrobenzyl)oxy]methyl (NBOM)40, 4-
methoxytetrahydropyran-4-yl (Mthp)41, triisopropylsilyloxymethyl (TOM)42, 2-
cyanoethoxymethyl (CEM)43, 2-cyanoethyl  (CE)44 group and 1,1-dioxo-1λ6-




Figure 5. Examples of 2’-OH protecting groups and their structures. 
1.5.4 Phosphate protection 
In general, a 2-cyanoethyl group is utilized as the phosphate protection when using 
the phosphoramidite approach. Taking into consideration that P(III) compounds 
are more vulnerable to nucleophilic attack than P(V) compounds, an oxidation 
reaction is needed to convert the phosphite into phosphate triester immediately 
after each coupling. After completion of the chain assembly, final cleavage of this 
protecting group is achieved by rapid β-elimination upon treatment with 
concentrated aqueous ammonia. However, the acrylonitrile which is generated 
during the ammonolysis is able to alkylate the amino base moieties46, and this 
phenomenon is more harmful when larger amounts of long oligonucleotides are 
required. To avoid this post-synthetic amino alkylation, alternative protecting 
groups, such as 2-benzamidoethyl or 2-[N-isopropyl-N-(4-methoxybenzoyl)-
amino]ethyl groups, have been screened47. In addition to these, an O-methyl 
phosphate protection has been employed for the same purpose. In this case, the 
methyl group can be removed by treatment with soft nucleophiles, usually with 1 
M disodium 2-carbamoyl-2-cyanoethylene-1,1-dithiolate in DMF.48 
1.6 Linkers 
In general, the growing oligonucleotide chain is immibilized to the solid support 
via 3’-O-succinyl linker. Succinic anhydride reacts with the unprotected 3’-OH 
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group of the nucleoside in the presence of a nucleophilic catalyst (i.e. DMAP) to 
form an ester linkage and the exposed carboxy function is then coupled to a support 
bound amino group with the aid of activators. The ester linkage is cleaved during 
the ammonolysis carried out after completion of the chain assembly. Apart from 
the succinyl linker, a large variety of linker chemistries have been developed for 
making the synthesis of oligonucleotides more versatile49,50. For instance, more 
base-labile linkers such as oxalyl51, malonic acid52 or Q-linker53 (hydroquinone-
O,O’-diacetic acid) may be utilized (Figure 6). The Q-linker, for example, can be 
rapidly cleaved by using milder reagents such as potassium carbonate, t-
butylamine, 5% aqueous ammonia or fluoride ions, and still the linker is stable 
enough under the general oligonucleotide synthesis conditions. Solid-supported 
nucleosides anchored through the Q-linker are commercially available54.  
 
Figure 6. Examples of linkers commonly used in oligonucleotide synthesis.  
1.7 Alternative coupling methods 
Besides the phosphoramidite chemistry, oligonucleotides may be obtained by the 
so-called phosphotriester55 and H-phosphonate56,57 chemistry (Figure 7). The 
advantage of phosphotriester chemistry is that the oxidation step is avoided, as the 
coupling gives directly the stable phosphate triester bond. In addition, the building 
blocks used in excess during the coupling step may be recovered, a fact of 
considerable importance when scaling up the process. However, the longer 
reaction times, the lower stepwise yield and, hence, overall efficiency, and the 
presence of coupling agents that may disturb the next coupling by capping the 5’-
OH group are features that need to be taken into consideration.  
On utilizing the H-phosphonate strategy, oxidation is not required after each 
coupling but only upon completion of the chain assembly. As in the phoshotriester 
chemistry, the excess of building blocks can be recovered on using the H-
phosphonate approach. Nevertheless, coupling agents may as well disturb the next 
coupling by capping the 5’-OH group. Accordingly, careful optimization may be 
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needed to find the workable coupling conditions. The stepwise coupling yield is 
slightly lower than in the phosphoramidite chemistry.  
 
Figure 7. Alternative H-Phosphonate and phosphotriester coupling methods. 
1.8 From small to large-Scale synthesis 
Undoubtedly solid-phase synthesis by the phosphoramidite chemistry is the 
method of choice for the small scale synthesis of oligonucleotides.  On scaling the 
synthesis from milligram to kilogram quantities, various challenges still remain to 
be overcome. The considerable excess of monomeric building blocks and large 
volumes of solvents used in the solid-phase synthesis increase notably the cost of 
the production, as also does the low loading capacity and high cost of the solid-
support. Although the solid-supported synthesis of oligodeoxyribonucleotides has 
already been performed in kilogram quantities, these factors nevertheless form an 
impediment for scaling up the process. The synthesis on an automated synthesizer 
is currently limited to 1 mole scale and the waste management cost is high58. In 
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addition, the use of explosive chemicals such as the tetrazole activator is not 
appropriate for safety reasons, but these safety risks have largely been eliminated 
by using non-explosive coupling activators for the same purpose25. In spite of 
development in technology and considerable reduction in consumption of 
phosphoramidite monomers, the scale and cost of the production still form a 
significant barrier for large-scale commercialization of oligonucleotides. 
In spite of the challenges indicated above, the solid phase synthesis of 
oligonucleotides still is the method currently used for the large-scale synthesis of 
ONs. The method has remarkably changed over the last two decades: the efficiency 
of the process has been carefully optimized, and serious efforts have been done for 
decreasing the amounts of reagents and solvents, which also has led to substantial 
reduction of the process time. In addition, various highly-toxic reagents have been 
replaced while preserving a high purity and efficiency of the synthesis59.  
1.9 Large-Scale purification of oligonucleotides 
In large-scale synthesis of oligonucleotides, purification upon cleavage from the 
support and removal of all temporal protecting groups is currently performed by 
two types of strategies. These methods are essentially conditioned by the final 
application of the oligomers, their overall length and the amount of truncated 
sequences produced during the synthesis. The method of choice also depends on 
the type of the oligonucleotide fabricated, as RNA, DNA and their modified 
analogs may require different type of purification. Among such techniques, 
chromatographic methodologies are at the vanguard of post-manufacture 
purification procedures for large scale synthesis of oligonucleotides. For instance, 
a standard purification strategy for the separation of oligonucleotides from 
undesired impurities is generally performed by either reversed phase HPLC or ion 
exchange HPLC, as shown in Scheme 4. The main difference between these two 
methods is essentially that reversed phase separation (RPHPLC) is based on the 
differences in matrix affinity whereas ion exchange separation (IEHPLC) depends 
on the length of the oligonucleotide or actually on the number of negative charges 
present in the molecule. In practice, RPHPLC allows an easy separation of the 
truncated sequences lacking the 5’-O-DMTr functional group from the 
corresponding 5’-O-DMTr protected oligomers, but it can also be used to remove 
many other impurities due to the high resolution of the technique. On the other 
hand, IEHPLC is the method of choice for the purification of RNA 
oligonucleotides upon detritylation, since the resolution and the capacity properties 




Scheme 4. Currently used solid-phase large scale oligonucleotide purification protocol. Model 




1.10 General remarks of Solution Phase Synthesis 
The development of solution phase synthesis as an alternative to the solid-
supported oligonucleotide chemistry has received significant interest due to more 
predictable scaling-up of the synthesis. Potentially lower cost, owing to limited 
solvent and reagents consumption and the lower cost of the support, makes 
solution phase synthesis worthwhile to study in more detail. In particular, linear 
liquid phase synthesis of oligonucleotides on a soluble support offers an alternative 
to the solid-phase synthesis, as the purification of the growing oligonucleotide may 
well be facilitated by an appropriate soluble support. As long as the soluble support 
is relatively small, nearly quantitative coupling by using only a stoichiometric 
amount of the building block appears achievable. Furthermore, the possibility to 
characterize the elongated sequences by using MS or NMR methods at any time 
of the synthesis is an important feature to take into consideration, although not all 
the supports allow this. The major challenge for successful large scale synthesis in 
solution phase is the convenience of separation of the growing oligonucleotide 
chain from small molecular reagents after each coupling cycle. As discussed 
below, novel innovations in separation technology may, however, offer solutions 
to this problem. 
As mentioned, on operating in solution, all byproducts and excess of reagents need 
to be removed after each coupling. Although chromatography is a good choice for 
small scale synthesis conditions, the technique is not convenient when scaling up 
the process. On the other hand, the use of modern membrane separation such as 
the cross-linked polybenzimidazole (PBI) facilitates the removal of small 
molecular reagents and byproducts by filtration and potentially offers a solution 
for this problem. Extraction is another possible alternative, but large solvent 
consumption may well limit the applicability of such approaches. In addition, 
extreme care needs to be exercised for prevention of hydrolysis of the phosphite 
triester moiety after coupling. Apart from these approaches, the development of 
precipitation techniques seems to be another realistic approach for the separation 
of growing oligonucleotides. The majority of the research on solution phase 
synthesis has been built around it. Precipitation may as well be applied from small 
to medium or even large quantities of oligonucleotides, affording in optimal cases 
nearly quantitative yields. Since a large number of soluble supports can utilize this 





1.11 Previous studies on solution phase synthesis of ONs by using 
soluble supports. 
A considerable amount of research has been focused on developing a solution 
phase oligonucleotide synthesis strategy on using a soluble-supported platform. 
Among various soluble supports, a wide variety of polyethylene glycol (PEG) 
polymers has been at the forefront61,62,63,64,65,66,67. PEG allows the use of acetonitrile 
as the solvent for the coupling reaction and the isolation of the growing 
oligonucleotide from excess reagents and small molecular weight impurities can 
be carried out by simple precipitation from diethyl ether and filtration. Since this 
carrier avoids the heterogeneity as the reaction medium, the method can be 
favorably used to produce large quantities of ONs. As an example of this, Bonora 
and co-workers62 used the standard phosphoramidite chemistry on a PEG soluble 
support (weight ranging between 5 and 12 kDa), and applied a new protocol called 
HELP Plus (High Efficiency Liquid Phase) to the large scale synthesis of ONs in 
a hundred of µmol scale. During the chain elongation cycle, 4 precipitations from 
Et2O and filtration were required, one after each synthetic cycle step (coupling, 
capping, oxidation and detritylation) (chart 1).  Analogously, the same protocol 
was utilized to produce phosphorothioate ONs in a mmol scale63,64 and even 
chimeric ONs containing phosphorothioate linkages at selected positions.65 In 
addition, a PEG support has been used for the synthesis of oligonucleotides by 
phosphotriester66,67 and H-phosphonate61 strategies. 
Since lower consumption of phosphoramidite building blocks is employed during 
the oligonucleotide assembly in comparison to the solid-phase synthesis, the 
process is cost-saving.  In addition, the methodology reported by Bonora’s group62 
allows monitoring the progress of the reaction by NMR spectroscopy at any time 
during the synthesis. Despite the fact that the protocol has very convenient features 
for the large scale synthesis of ONs in solution, the use of 4 precipitations and 
recrystallizations in ethanol after each chain extension cycle makes the process 
time-consuming and, hence, any effort aimed at reducing the precipitation and 
recrystallization steps would be desirable. Since the feasibility of the method for 
the large-scale synthesis of oligonucleotides has been demonstrated for the 
synthesis of oligomers up to 20 nucleotides in length, introducing the above-






Chart 1: Strategy of Bonora’s phosphoramidite approach62 on using the HELP Plus protocol on 
a PEG soluble support. 
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More recently, a new approach for the solution phase synthesis of 
oligonucleotides, based on (adaman-1-yl)acetyl as a soluble support, was 
introduced by van der Marel’s group68. The advantage of this support comes from 
feasibility of an extractive work-up procedure as a method for removal of small 
molecular impurities and excess reagents. Eight extractions were required in each 
synthetic cycle in order to remove completely the activator, DMTr byproduct, 
small molecular weight reagents and unreacted excess of monomeric building 
blocks: four times after the oxidation (Na2S2O3, 10% KHSO4, 10% NaHCO3 and 
brine) and another four times after the detritylation step (heptane/Et2O, 
EtOAc/H2O, 10% NaHCO3 and brine) (chart 2). The extractive work-up 
procedure allowed a quantitative separation of the growing oligonucleotide chain 
from the small excess reagents and impurities, providing pure product in high 
yield. In addition, the efficiency of the synthesis was demonstrated up to the 6-mer 
level. N3-Pivaloyloxymethyl protected thymidine was used to increase the 
solubility of the growing oligonucleotide. Since this methodology is amenable to 
scale up, an industrial manufacturing platform could be developed. However, it 
would be highly desirable to reduce the number of extractions per chain extension 






Chart 2: The strategy of van der Marel’s group for the solution-phase synthesis of ONs by the 
phosphoramidite approach on using (adaman-1-yl)acetyl68 as a soluble support. 
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An imidazolium ion tag, having tetrafluoroborate as a counterion, has been utilized 
as a soluble support for the synthesis of oligonucletodies by the group of Damha69. 
This ionic liquid supported synthesis allowed an easy purification of the growing 
oligonucleotide chain from excess reagents and impurities by applying a 
combination of precipitative and extractive techniques. Selective precipitation 
without temperature cycling was carried out four times per synthetic cycle: twice 
upon the coupling and prior to oxidation, and another twice upon the detritylation 
step. In both cases a mixture of EtOAc/Et2O was successfully used for the purpose, 
allowing a rapid elimination of excess reagents and soluble by-products. In 
addition, convenient extractive work-up on using initially 5% w/v aqueous 
NaHSO3 in DCM and later in water were carried out upon the oxidation step for 
the removal of resultant salts and uncoupled soluble supported nucleotides. 
Successful application of this support was demonstrated by the synthesis of 
oligomers in different length: four dinucleotides, a thymidine homo-trimer and a 
thymidine homo-tetramer (chart 3). Since the protocol allows scaling up due to 
the homogeneous reaction processes and the higher (30 fold) loading capacity of 
the ionic soluble support compared to the CPG solid polymers, the industrial 
manufacturing platform appears possible to achieve. Nevertheless, similarly to the 
adamantly-derived core, the reduction of the number of operations (particularly 





Chart 3: Strategy of Damha’s group for the solution-phase synthesis of ONs by the 
phosphoramidite approach on using an imidazolium ion tag69 as a soluble support. 
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More recently, attempts to employ an adamantine-based and two different phenolic 
cores named tetrakis(p-hydroxyphenyl)methane (TPM, four-arm core) and 
hexakis(p-hydroxyphenyl)xylene (HPX, six-arm core) were investigated by 
Richert and colleagues70,71,72. In these cases, only one coupling was carried out on 
using phosphoramidite dinucleotide building blocks for the synthesis of branched 
DNA hybrids with four arms to an adamantine-based support, and also to four or 
six arms to the phenolic cores. Despite the fact that these studies do not contain 
any oligonucleotide synthesis, the usefulness of these kinds of supports comes 
from the point of view of their precipitative properties. For instance, precipitation 
of TPM and HPX-derived cores from hexane removed easily excess of dimeric 
building blocks. However, since only one coupling and purification by 
precipitation were carried out during the process, no real synthetic method was 
developed and, hence, no oligonucleotides were really prepared.  
 
 




2. AIMS OF THE THESIS 
The research on which this thesis is based was initiated as part of the MEMTIDE 
project “Novel soluble supports and linkers for membrane enhanced synthesis of 
oligonucleotides, a new paradigm for large scale synthesis”, under the FP7 Marie 
Curie Actions. The project consortium was composed of 6 partners: Imperial 
College (UK), University of Barcelona (Spain), University of Turku (Finland), 
Lonza (Switzerland), Janssen (Belgium) and Evonik-MET (UK). The main 
objective comprised the development of a scalable oligonucleotide and peptide 
synthesis platform on using the emergent Organic Solvent Nanofiltration (OSN) 
purification technique. The role of the University of Turku was, in collaboration 
with researchers at Imperial College of London, to develop a large scale method 
for preparation of oligonucleotides useful for the membrane platforms. 
Accordingly, the primary aims of the present theses were i) to develop such new 
soluble supports for solution phase synthesis of oligonucleotides that could be 
exploited in membrane-supported approaches, ii) to introduce alternative 
protecting group strategies compatible with the OSN methodology, and III) to 
design novel synthesis protocols compatible with the large scale synthesis and the 
membrane filtration technique. The secondary aim was to develop in parallel a 
related methodology that could be used in normally equipped research laboratories 
for the preparation of oligonucleotides in hundreds of milligrams scale, which is 
the amount often required for extensive physico-chemical and structural studies of 





3. RESULTS  
3.1 Synthesis of oligodeoxyribonucleotides on acetylated and 
methylated β –cyclodextrins. 
3.1.1 Assembly of oligonucleotides from 5’-O-(4,4’-dimethoxytrityl)-
protected building blocks on acetylated β–cyclodextrin.  
The objective of this subproject was to describe a new protocol for oligonucleotide 
synthesis based on utilization of acetylated β-cyclodextrin (β-CD) as a soluble 
support. β-CD (23) is a cyclic oligosaccharide that consists of 7 (α-1,4)-linked α-
D-glucopyranose units. The general appearance of the structure gives an 
impression of a truncated torus, with a lipophilic inner cavity and a hydrophilic 
outer part (Figure 9). Accordingly, secondary OH groups are positioned on the 
wider extremity, whereas the primary OH groups are located on the narrower 
bottom of the torus.  
 
Figure 9. Structure of β-CDs. 
The use of β-CD as a soluble support was expected to enable a workable large-
scale synthesis of ONs. First of all, it is commercially available and can be found 
easily in marketed pharmaceutical products. In addition, compared to many other 
supports, β-CD is inexpensive (~5 USD/Kg)73 and would, hence, have a very low 
contribution to the overall cost of the preparation of oligonucleotides. From the 
point of view of nanofiltration, the size of β-CD is convenient as it is still small 
enough to allow normal solution phase chemistry and characterization of the 
reaction products by MS or NMR methods at any stage of the synthesis. 
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Furthermore, acetylated β-CDs are hydrophobic enough to allow a convenient 
purification of the growing oligonucleotide chain from excess reagents and 
impurities by flash column chromatography with small solvent consumption. 
Apart from the advantages indicated above, a few challenges were encountered 
during this study. All the hydroxyl groups of β-CD have to be kept protected during 
the oligonucleotide synthesis to prevent the phosphoramidite building blocks to 
react with them and to increase the solubility into organic solvents.74 The most 
obvious approaches for the hydroxyl function protection are acylation75 or 
alkylation76,77,which both expectedly improve the solubility in organic solvents, 
such as acetonitrile and dichloromethane often used in oligonucleotide synthesis. 
Monofunctionalization of β-CD is another problem to overcome. The aim was to 
immobilize the 3´-terminal nucleoside to β-CD by the so-called click-reaction, i. 
e. by Cu(I) catalyzed 1,3-dipolar cycloaddition between and alkyne and azide.78 
That is why, monoazidation of β-CD was attempted.  Conventional synthesis starts 
with tosylation of one primary hydroxyl functions by treatment with one equiv. of 
tosyl chloride to obtain 6-O-tosyl-β-CD (24).79 In practice, derivatization of only 
one OH group is difficult to achieve, and the presence of a mixture of mono-, di-, 
and even tri-functionalized β-CD is usually observed. Although this problem does 
not disturb to the subsequent reactions, the monofunctionalized product is difficult 
to obtain in pure state before acetylation or methylation of the remaining hydroxyl 
groups, which disturbs characterization. Despite the fact that there are several 
easily accessible anchoring sites, it appeared useful to use only the 
monofuctionalized product for the chain assembly, since it was the simplest study 
model and also was less difficult due to steric hindrance. The tosyloxy group is 
subsequently displaced with azide ion, giving the monofunctionalized 6-azido-6-
deoxy-β-CD (25)80. In our first study, the remaining free hydroxyl groups were 
acetylated with acetic anhydride in pyridine75 to afford 26. 
Afterward the 3´-terminal nucleoside was then converted to a 3´-O-(hex-5-ynoyl) 
derivative.  The 5´-hydroxy function of thymidine was first protected by treatment 
with DMTrCl in pyridine (to obtain 28), and the 3´-hydroxy group was acylated 
with hex-5-ynoic anhydride prepared in situ. The 5´-O-DMTr-3´-O-(hex-5-
ynoyl)thymidine (29) obtained was then subjected to the click reaction with the 
azido function of β-CD 26 to yield 30a, as shown in Scheme 6. Among the great 
diversity of linkers that can be used for immobilization of the 3’-terminal 
nucleoside, the 3′-O-(hex-5-ynoyl) linker that bears a terminal alkyne was chosen, 
owing to the known efficiency of the Cu(I) promoted chemoselective conjugation 
reaction with the azide group.81 ,82 The reaction generates a stable 1,2,3-triazole 
structure, which remains intact during the oligonucleotide synthesis, even under 
acidic and oxidizing conditions used in the synthesis, while the ester function 
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allows conventional release by ammonolysis. Support 30a was finally detritylated 
by treatment with a solution of 3% dichloroacetic acid in DCM followed by 
DCM/HCO3- extractive work-up to obtain 30b. The identity and homogeneity of 
support 30b was verified by ESI-MS and RPHPLC.  
 
Scheme 6. Preparation of peracetylated CD support for oligonucleotide synthesis.  Reagents and 
conditions: (i) TsCl, Py;(ii) NaN3, KI, DMF;(iii) Ac2O, Py;(iv) DMTrCl, Py (v) 1. 5-hexynoic 
acid, DCC, dioxane, 2. 28, Py; (vi); CuSO4, sodium ascorbate and 29; (vii) 3% DCA/DCM.  
To test the applicability of support 30b to the synthesis of oligonucleotides,  
a 5’-TTT-3’-β-CD trimer was first assembled on using 1.5 eq of commercially 
available 5′-(4,4′-dimethoxytrityl)thymidine 3′-(2-cyanoethyl-N,N-
diisopropylphosphoramidite) (31) building block on the peracetylated β-CD 
soluble support. Tetrazole (1.5 eq), added as a 0.45 M solution in MeCN, was used 
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as an activator. Upon 1h stirring under nitrogen, an aqueous iodine oxidation 
solution (I2:H2O:THF:2,6-lutidine 0.43g: 4mL: 8mL: 2mL; 1.2 equiv.) was added 
and the reaction was left for 30min at r.t. After the phosphoramidite coupling step 
and subsequent aqueous iodine oxidation, the mixture was concentrated under 
reduced pressure and the excess of iodine was removed by extractive aqueous 
sodium bisulfite / DCM work-up. The product was retained quantitatively in the 
organic phase. The organic phase was dried over anhydrous sodium sulfate, 
filtrated and evaporated to dryness. The identity of the product before the 
detritylation step was confirmed by MS, which also verified the absence of starting 
material 30b. The 5´-O-DMTr group was then removed by 1h treatment with 3% 
dichloroacetic acid in DCM. Afterwards, the mixture was washed with saturated 
aqueous sodium bicarbonate. The aqueous phase was back-extracted twice with 
DCM, the combined organic phases were dried over sodium sulfate, and the 
solvent removed under reduced pressure. The identity and purity of the product 
was confirmed by MS and RPHPLC analysis, respectively. Although the 
detritylated dimer still contained DMTrOH impurities, the product was subjected 
to the next coupling without further purification. This synthetic coupling cycle was 
repeated in a similar manner by using the same building block (31). Upon 
completion of the trimer assembly, the chain was cleaved from the support by 
aqueous ammonia treatment. ESI-MS confirmed the identity of the expected 
product, and the homogeneity of the trimer was assessed by RPHPLC analysis 
(Figure 2A, article I). According to the UV-spectrophotometric assay in 
comparison to the support 30b, the overall yield of the trimer was 85%, 
corresponding to 92% stepwise yield.  
Scheme 7 illustrates the general procedure utilized for the synthesis of the 5’-TTT-






Scheme 7. General strategy for the assembly of oligodeoxynucleotides from 5’-O-DMTr 
protected thymidine building blocks on acetylated β-CD. 
The low molecular weight of the CD support, allowed mass spectrometric analysis 
at any time of the synthesis and, hence, verification of the completeness of 
coupling. However, upon final ammonolytic treatment, the acetyl groups on the β-
CD were also cleaved and the isolation of the oligonucleotide chain from the 
cyclodextrin support became difficult.  In addition, hydrophobic DMTr alcohol 
and unreacted building blocks were accumulated in the reaction mixture. In spite 
of this, synthesis of a trimer was successful.  
3.1.2 Assembly of oligonucleotides from 5’-O-(1-methoxy-1-methyl-ethyl)-
protected building blocks on acetylated β–CD. 
Since the shortcomings mentioned above did not permit assembly of longer 
sequences, the coupling cycle was simplified by replacing the 5’-O-DMTr 
protection with a 5’-O-(1-methoxy-1-methylethyl) protecting group and the 
synthesis of the 5’-TTT-3’ trimer was repeated by using chromatographic 
purification for removal of impurities and the excess of reagents after each 
coupling cycle.  
The main reason for the replacement of the 5´-O-DMTr protection with an acetal 
protection was that an equilibrium between tritylated and detritylated material was 
observed to be settled during the detritylation reaction (Scheme 8). To push the 
reaction to completion (to obtain detritylated product) different approaches can be 
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used, including: 1) increasing the acidity of the solution; 2) removing the DMTr 
cation from the mixture; 3) using a scavenger to trap the DMTr cation. The first 
alternative is not possible, since an increase of the acid concentration results in 
cleavage of purine bases.83 In fact, this depurination is the major limitation of all 
current protocols applied to synthesis of oligodeoxyribonucleotides. The second 
alternative can be realized by simply making the solution more diluted by 
increasing the volume of the reaction mixture. However, this will in large scale 
synthesis lead to excessive solvent consumption. Finally, the third alternative, use 
of scavangers, is a method that has been rather extensively studied.69,84,85,86,87,88 
While undoubtedly feasible, even this approach increases reagent consumption and 
complicates separation steps. In addition to pyrrole84,85,86, triethylsilane87,88 and 
borane-amine complexes88, even methanol84,87 or ethanol69,84 have been used as 
scavengers. Although the equilibrium is significantly shifted towards the 
formation of the detritylated material, the approach does not seem to eliminate 
completely this problem.69  
 
Scheme 8. Equilibrium reaction during the DMTr deprotection in ON synthesis. 
For these reasons, a new approach involving the replacement of the conventional 
DMTr by a 5’-O-(1-methoxy-1-methylethyl) group was studied. Upon acidic 
treatment, this acetal protection generates an easily removal volatile product 
dimethyl acetal of acetone. In addition, dichloroacetic acid was replaced by 
volatile HCl. After the deprotection step, HCl can be removed easily from the 
reaction mixture by evaporation under reduced pressure. Since 5’-O-(1-methoxy-
1-methylethyl)-protected building blocks are not commercially available, they 
were prepared as described below. 
The synthesis was initiated by protection of the 3’-OH group of nucleosides    32a-
c with a tert-butyldimethylsilyl (TBDMS) group (Scheme 9). On using thymidine 
(27) as a starting material, both 3’- and 5’-OH groups were first silylated, and the 
5´-O-protection was selectively removed with aqueous TFA89 in THF to obtain 
34a. 3´-O-Silylated N4-benzoyl-2´-deoxycytidine (34b) and N6-benzoyl-2´-
deoxyadenosine (34c) were, in turn, prepared by silylation of the commercially 
available base protected 5´-O-DMTr-nucleosides (32a,b) to obtain 33b,c, followed 
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by acidolytic detritylation. All three nucleosides were then subjected to acid-
catalyzed acetalization with 2-methoxypropene to obtain 35a-c. Cleavage of the 
3’-O-TBDMS group with tetrabutylammonium fluoride (TBAF) in THF then 
resulted in 3´-unprotected nucleosides 36a-c, which were phoshitylated to the 
desired acetal protected phosphoramidite building blocks (37a-c). In addition, the 
3′-O-(hex-5-ynoyl) linker was attached to the 3’-OH- group of 36a to obtain 38.  
Scheme 9. General strategy for the synthesis of acetal protected nucleosidic building blocks. 
Reagents and conditions: (i) TBDMSCl, Im, DMF; (ii) TFA, aq. THF for 33a; 3% 
DCA/MeOH/DCM for 33b-c; (iii) 2-methoxypropene, TsOH, dioxane; (iv) TBAF, THF; (v) 1-
chloro-1-(2-cyanoethoxy)-N,N-diisopropylphosphinamine, Et3N, DCM; (vi) 1. 5-hexynoic acid, 
DCC, dioxane, 2. 36a, Py; 
For comparative purpose, assembly of a 5’-TTT-3’ trimer was performed on the 
peracetylated β-CD on using 5’-O-(1-methoxy-1-methylethyl)thymidine 3′-(2-
cyanoethyl-N,N-diisopropylphosphoramidite) (37a) building block. The coupling 
was carried out using 1.5 eq of 37a and 4,5-dicyanoimidazole (1.5 eq, 0.25 M 
solution in dry MeCN) as an activator. After 1h, the phosphite triester was oxidized 
to the phosphate triester by treatment for 30 min with the standard aqueous iodine 
solution (0.2M I2 in 2,6-lutidine/H2O/THF 2:4:8). The reaction mixture was then 
concentrated under reduced pressure and sodium bisulfite/DCM extractive work-
up was used to remove the excess of iodine. The organic phase was dried over 
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sodium sulfate, filtrated and evaporated to dryness. The expected product was 
identified by ESI-MS analysis. Traces of lutidine were still observed in the mixture 
even after evaporation under reduced pressure. 5’-O-Deprotection was then 
performed by adjusting the pH to 4 with HCl (using a 0.1 M stock solution in a 2:1 
(v/v) mixture of dioxane and MeOH) and allowing the reaction to proceed for 30 
min. Both HCl and the released dimethyl acetal of acetone were then removed by 
simple evaporation under reduced pressure. 
The cleavage of the 5’-O-(1-methoxy-1-methylethyl) group was fast enough to 
almost entirely avoid depurination (Figure 3, article I). Coevaporation with dry 
pyridine removed any traces of acid still present in the solution. As regards the 
mechanism of the acid-catalyzed removal of the 5’-O-(1-methoxy-1-methylethyl) 
group in MeOH, the rapid initial protonation of the 5’-O-function is followed by 
departure of 2-methoxypropane oxocarbenium ion that is converted to 2,2-
dimethoxypropane by nucleophilic attack of MeOH and subsequent deprotonation 
(Scheme 10).  
 
Scheme 10. Mechanism for the deprotection of the 5’-O-(1-methoxy-1-methyl-ethyl) protecting 
group. 
After the 5´-deprotoection, a flash chromatographic purification was carried out to 
remove the excess of unreacted building block, and, hence, avoiding the 
accumulation of impurities after repeated couplings. This chromatographic 
purification gave the desired dimer free of any contaminants. The coupling cycle 
was then repeated in a similar manner and upon completion of the trimer, the 
oligonucleotide was released from the β-CD soluble support by ammonolysis. ESI-
MS confirmed the identity of the expected trimer, and RPHPLC analysis (Figure 
2B, article I) indicated high purity of the product. Compared to the assembly by 
using 5’-O-DMTr protected building blocks, this study showed slightly better yield 
in the synthesis of 5’-TTT-3’ in solution. Accordingly, an overall yield of 87% 
(according to UV-analysis in comparison to the support 30b), corresponding to 
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93% stepwise yield was obtained. Scheme 11 represents the general procedure 














































Scheme 11. General strategy for the assembly of oligodeoxynucleotides on using 5’-O-(1-
methoxy-1-methylethyl) protected thymidine building blocks on a peracetylated β-CD soluble 
support. 
3.1.3 Assembly of oligonucleotides from 5’-O-(1-methoxy-1-methyl-ethyl)-
protected building blocks on methylated β–CD. 
Since peracetylated β-CD does not withstand the final ammonolytic treatment, it 
appeared attractive to replace it with a more stable methylated β-CD, which upon 
ammonolytic treatment may be removed by extractive work-up procedures without 
the need of RPHPLC purification. In addition, a longer oligonucleotide was 
assembled by using a hetero-sequence composed of 5’-O-(1-methoxy-1-
methylethyl) protected building blocks (37a-c).  
Methylation was carried out with a mixture of sodium hydroxide and methyl iodide 
in DMSO76,77 to afford 39. As with the acetylated β-CD, the azido function of 39 
was subjected to Cu+ promoted 1,3-dipolar cycloaddition81,82 to attach the 3´-
terminal nucleoside bearing a 3´-O-(hex-5-ynoyl) linker (29) to the CD support. 
Finally, detritylation of support 40a was performed by treatment with HCl in a 2:1 
mixture of dioxane and MeOH followed by removal of volatiles under reduced 
pressure to afford 40b (Scheme 12). Subsequent coevaporation with pyridine and 
MeCN eliminated any acid still present in the mixture. Finally, chromatographic 
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purification was carried out in order to remove trityl impurities, such as 
DMTrOMe and DMTrOH. The identity and homogeneity of support 40b was 
confirmed by ESI-MS and RPHPLC, respectively. (Figure 1B, article I). 
 
Scheme 12. Preparation of permethylated β-CD support for oligonucleotide synthesis. Reagents 
and conditions: (i) NaOH, MeI, DMSO;(ii) CuSO4, sodium ascorbate and 29; (iii) HCl in 
(dioxane:MeOH) (2/1).  
As regards oligonucleotide synthesis on the methylated β-CD-T-5’-OH, 40b was 
firstly subjected to 6 h coupling by using 37a (1.5 eq) as the building block and 
4,5-dicyanoimidazole (1.5 eq, 0.25 M solution of 4,5-dicyanoimidazole in 
anhydrous MeCN) as the activator. Upon completion of the coupling, oxidation of 
the phosphite triester to phosphate triester was carried out as described above. The 
mixture was dried over sodium sulfate, filtrated and the solvent removed by 
evaporation under reduced pressure. The expected product was confirmed by ESI-
MS analysis. Traces of lutidine were still observed in the mixture. The 5’-O- acetal 
protecting group was removed by adjusting the pH to 4 (pH paper indicator) with 
HCl (0.1 M solution in a 2:1 mixture of dioxane and MeOH). Flash column 
chromatography in DCM/MeOH removed the byproducts formed from the 
unreacted building block. Upon completion of the synthetic coupling cycle from 
monomer to dimer, the protocol was repeated three times in a similar manner, but 
using in a sequential order 37b, 37c and again 37a as building blocks to obtain 
pentamer 5’-TdAdCTT-3’. The identity and homogeneity of the products were 
confirmed upon each coupling cycle by ESI-MS and RPHPLC. Finally the 
oligonucleotide was released from the permethylated β-CD support by 
ammonolysis, followed by extractive work-up in DCM/H2O. Since the 
permethylated β-CD could be quantitatively removed by extraction, isolation of 
the pentamer was considerably simplified compared to the situation on using the 
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acetylated support. ESI-MS confirmed the structure of the expected pentamer, and 
the homogeneity of the product was determined by RPHPLC analysis (Figure 4, 
article I). The overall yield of the pentamer synthesis was 52% (according to 
gravimetric measures in comparison to the support 40b), corresponding to 85% 
stepwise yield. Scheme 13 represents the general procedure used for the synthesis 
of 5’-TdAdCTT-3’ on using 37a-c as the building blocks.  
 
Scheme 13. General strategy for the assembly of oligodeoxynucleotides on using 5’-O-(1-
methoxy-1-methylethyl) protected building blocks on methylated β-CD. 
Although the protocol described in Scheme 13 turned out quite successful, it still 
suffered from some experimental inconveniences. In spite of extractive sodium 
bisulfite work-up after the oxidation step, traces of 2,6-lutidine were present in the 
mixture and had to be neutralized with HCl upon adjusting the pH to 4 for the 
removal of the 5´-O-protecting group. Accordingly, a time consuming titrimetric 
procedure had to be used to adjust the pH. Attention needed to be paid for this 
operation as too low pH led to increased amount of depurination. Another 
experimental inconvenience is the chromatographic separation of the growing 
oligonucleotide chain from excess of reactants, other reagents and impurities. 
Despite the fact that chromatography is a good choice for small scale synthesis, 
the technique is not convenient when scaling up the process. From the practical 




3.2 Synthesis of oligodeoxyribonucleotides on a pentaerythritol-
derived soluble support. 
The underlying idea of this study was to describe a novel protocol for the synthesis 
of ONs by the phosphoramidite approach utilizing a tetrapodal pentaerythritol core 
as a soluble support. The interest on this symmetrical pentaerythritol-derived 
structure aroused from the necessity of searching a soluble support compatible 
with the membrane filtration purification technique. Although that was the original 
idea and the results of membrane filtration studies were encouraging, we found 
that precipitation offered an excellent alternative for the purification of the 
growing support-bound ON chain. In addition, the protocol employed 
commercially available building blocks, which undoubtedly would benefit to 
research groups that sporadically require DNA synthesis. Furthermore, since the 
branching molecule can be used to carry four ON arms, the atom economy of the 
synthesis is significantly increased compared to cyclodextrin supports. For that 
reason, the use of the pentaerythritol core as a soluble support was expected to 
permit large-scale synthesis of ONs.  
One of the attractive advantages of this support is that pentaerythritol tetrabromide 
used as a starting material is commercially available (755 USD/Kg). Although 
more expensive than β-CD, it still has a low contribution to the overall cost of the 
preparation of oligonucleotides. The other advantages of the pentaerythritol-
derived soluble support includes: 1) easy preparation in the laboratory; 2) chemical 
and mechanical stablity (withstands the reaction conditions used during the 
oligonucleotide synthesis); 3) good solubility properties (not limited by the 
solvent); 4) several easily accessible anchoring sites. In addition, from the point of 
view of nanofiltration, the size of support is convenient as it is still small enough 
to permit normal solution phase chemistry and characterization of the reaction 
products by MS or NMR methods at any stage of the synthesis. Furthermore, one 
significant attribute of this support is that purification of the growing 
oligonucleotide chain can be achieved by quantitative precipitation from MeOH. 
Preparation of the support started from commercially available pentaerythritol 
tetrabromide (41), which upon treatment with 4-hydroxybenzaldehyde, KOH and 
TBAI in DMF at 120ºC afforded (42). The aldehyde was then reduced to alcohol 
with NaBH4 in MeOH, to obtain (43). The hydroxyl function was displaced by 
chlorination with SOCl2 in dioxane to afford (44), and the chloride was 
subsequently displaced with azide ion (45, 55% overall yield from 41).  
5´-O-DMTr-thymidine (28) was converted to a 3´-O-(pent-4-ynoyl) derivative by 
acylation with pent-4-ynoic anhydride prepared in situ. The 5´-O-DMTr-3´-O-
(pent-4-ynoyl)thymidine (46) obtained was then subjected to Cu(I) promoted 1,3-
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dipolar cycloaddition to attach the alkyne linker (46) to support 45. After 
completion of conjugation by this so-called click reaction, clustered support 47 
was detritylated with a solution of 10 mM HCl in MeOH/DCM (1:1 v/v). Addition 
of pyridine, followed by evaporation under reduced pressure and chromatographic 
purification, afforded the nucleoside cluster, tetrakis{[4-({4-[3-(thymidin-3’-O-
yl)-3-oxoprop-1-yl]-1-H-1,2,3-triazol-1-yl}methyl)phenoxy]- methyl}methane 
(48), as shown in scheme 14. The identity and homogeneity of support 48 was 
verified by ESI-MS and NMR spectroscopy (Figure S3, supporting information, 


























47 : R' = DMTr
48 : R' = H
i
42 : R = CHO
43 : R = CH2OH
44 : R = CH2Cl




















Scheme 14. General strategy for the immobilization of thymidine on a pentaerythritol-derived 
soluble support. Reagents and conditions: (i) 4-hydroxybenzaldehyde, KOH, TBAI, DMF, 120ºC; 
(ii) NaBH4, MeOH, rt; (iii) SOCl2, dioxane, 70ºC; (iv) NaN3, DMF; (v) pent-4-ynoic anhydride, 
DMAP, pyridine; (vi) aq CuSO4, sodium ascorbate, dioxane, 40ºC; (vii) HCl (13 mmol/L) in 
MeOH/DCM (1:1 v/v), rt. 
To test the applicability of the clustered nucleoside support 48 to the synthesis of 
oligonucleotides, three trimer heterosequences, 5’-dCdCT-3’, 5’-dGdCT-3’ and 
5’-dAdCT-3’, and one pentamer containing all the bases, 5’-dAdGdCdCT-3’,  
were assembled by using 6 equiv. (1.5 eq per free OH group on cluster 48)  
of commercially available 5′-(4,4′-dimethoxytrityl)-3′-(2-cyanoethyl-N,N-
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diisopropylphosphoramidite) building blocks (31, 49a-c). 4,5-Dicyanoimidazole 
(6 eq), added as 0.25 M solution in MeCN, was used as an activator. Upon 2h 
stirring under nitrogen, the standard aqueous iodine oxidation solution 
(I2:H2O:THF:2,6-lutidine 0.43g: 4mL: 8mL: 2mL; approximately 1.3 eq per mol 
of building block 31, 49a-c) was added until the dark color remained and the 
reaction was left for 5 min at r.t. The excess of iodine was removed by the addition 
of 1 M solution of trimethyl phosphite in DMF (approximately 0.3 eq of trimethyl 
phosphite per mol of building block 31, 49a-c). Completion of the  oxidation 
reaction was confirmed by RPHPLC analysis (Figure 1, plots i-ii, article II). The 
mixture was then subjected to precipitatation from cold MeOH (267 mL/g). While 
the support precipitated quantitatively, small molecular weight reagents and 
impurities remained in solution. The product was then subjected to detritylation by 
using 13 mmol/L HCl in MeOH/DCM (1:1 v/v) and the progress of the reaction 
was monitored by TLC (approximately 15min). Upon detritylation, the acid was 
neutralized by addition of pyridine, the reaction mixture was concentrated to oil 
and quantitative precipitation of the supported oligonucleotide from cold MeOH 
was carried out for removal of undesired excess reagents and impurities. 
Afterwards, the white precipitate was isolated, dried under vacuum and the identity 
and homogeneity of the product was confirmed by ESI-MS and RPHPLC, 
respectively. Upon generation of unprotected 5’-OH group, the coupling cycle was 
repeated in a similar manner. The three trimers, 5’-dCdCT-3’, 5’-dGdCT-3’, 5’-
dAdCT-3’, and pentamer 5’-AGCCT-3’, were cleaved from the pentaerythritol 
support by treatment with concentrated aqueous ammonia. Scheme 15 represents 
the general protocol for  the oligonucleotide synthesis on using the clustered 
pentaerythritol support (48) and commercially available building blocks (31 and 
49a-c). Finally, ESI-MS confirmed the identity of the compounds (Table 1, article 
II) and RPHPLC analysis revealed that nearly homogeneous products were 
obtained (Figure 1, plots viii-xi, article II). Only small traces of debenzoylation 
and depurination of adenosine were observed (Figure 1, plots iv-vii, article II). The 
overall yield of the pentamer synthesis was 43% (according to UV spectroscopic 
analysis in comparison to the support 48), whereas the trimers were obtained in 




Scheme 15. General strategy for the assembly of oligodeoxynucleotides by using 5’-O-DMTr-
protected building blocks on a pentaerythritol-derived soluble support. 
As with the acetylated and methylated β-CDs supports, the pentaerythritol support 
also allowed a precise mass spectrometric analysis at any stage of the synthesis. 
From the practical point of view, the main advantage of this support is the 
convenient precipitation technique applied to the isolation of the growing support-
bound oligonucleotide chains. In fact, excess reagents and impurities are soluble 
in MeOH, while the supported nucleotides precipitate in quantitative yields from 
this solvent. Accordingly, it appeared attractive to use the pentaerythritol support 
also for the assembly of short oligoribonucleotides (RNA) in solution.  
3.3 Synthesis of oligoribonucleotides on a pentaerythritol soluble 
support. 
3.3.1 Assembly of oligoribonucleotides from 2´-O-(2-cyanoethyl)- 5’-O-(1-
methoxy-1-methylethyl)-protected building blocks. 
This study was aimed at providing a basis for the synthesis of short 
oligoribonucleotides on using the pentaerythritol-derived soluble support. During 
this study, a few relevant challenges were encountered. The first one was the 
difficulty to achieve quantitative Cu(I) promoted 1,3-dipolar cycloaddition by 
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using a mixture of aqueous CuSO4, and sodium ascorbate in 1,4-dioxane as a 
solvent, since the reaction didn’t proceed completely due to the precipitation of the 
pentaerythritol-derived soluble support in the presence of a small volume of water. 
To overcome this problem, catalytic amount of CuI and sodium ascorbate in 
dimethylacetamide (DMAc) was used followed by degassing in order to remove 
the oxygen during the reaction. These changes together with control of the water 
content in the solution resulted in formation of the expected product in nearly 
quantitative yield. 
Preliminary studies showed that large hydrophobic 2’-O-protecting groups, such 
as TBDMS, prevented precipitation of the support-bound oligonucleotide from 
MeOH. Apart from 2’-O-TBDMS, 2’-O-methyl, 2’-O-TOM, 2’-O-PivOM and 2’-
O-TC protections, no other phosphoramidite building blocks are commercially 
availaible and, hence, the monomeric blocks had to be prepared. To ensure 
precipitation, relatively small 2-cyanoethyl and 1-methoxy-1-methylethyl groups 
were used for the 2´-O- and   5´-O protection, respectively.   
The starting materials of the synthesis of these building blocks were base moiety 
protected 2'-O-(2-cyanoethyl)-3',5'-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl) 
ribonucleosides (50a,b',c,d), which were prepared as described in the literature90. 
Selective hydrolysis of the 5’-O-Si bond with aqueous TFA in THF was carried 
out to obtain 51a-d, and the unprotected 5’-OH group was subjected to 
acetalization by treatment with 2-methoxypropene in THF in the presence of a 
catalytic amount of p-toluenesulfonic acid, to afford 52a-d. Desilylation of the 3’-
O-TIPDS was a problem to overcome. The removal was first attempted with 
TEA·3HF, but partial cleavage of the 5’-O-(1-methoxy-1-methylethyl) group 
turned out to be an impediment. TBAF was next employed for desilylation, but 
unfortunately partial cleavage of the 2’-O-(2-cyanoethyl) group was found to be a 
limitation. Finally, treatment with NH4F in MeOH resulted in the desired 
desilylation leaving both 2’-O- and 5’-O protections intact (53a-d). Unfortunately, 
in some cases partial cleavage of base moiety protection took place. For instance, 
adenosine (53d’) lost the dimethylaminomethylene protection entirely and 
cytidine (53c’) partially. As the base moieties have to be kept protected during the 
oligonucleotide synthesis (except uracil), 53d´ and 53c´ were reprotected. In the 
case of adenosine, the dimethylaminomethylene protection was reintroduced 
(53d), whereas cytidine was N-benzoylated (53c’’). In addition, upon NH4F 
treatment, the N-benzoylated uridine derivative (52a) yielded a mixture of 
benzoylated (53a) and debenzoylated (53a’) products. Finally, phosphitylation of 
the free 3’-OH group was carried out by treatment with 1-chloro-1-(2-
cyanoethoxy)-N,N-diisopropylphosphinamine to afford the phosphoramidite 
building blocks (54a’,b,c’’,d). Additionally, for immobilization of the 3’-terminal 
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nucleoside to the pentaerythritol-derived tetraazido support (45), the 3´-OH group 
of nucleoside 53a was esterified by acylation with pent-4-ynoic anhydride 
prepared in situ, affording 55a. The synthesis of the monomeric building blocks is 
outlined in Scheme 16. 
 
Scheme 16. Synthesis of nucleosidic building blocks. Reagents and conditions: (i) TFA, aq THF, 
0ºC; (ii) 2-methoxypropene, TsOH, THF; (iii) NH4F, MeOH; (iv) 1-chloro-1-(2-cyanoethoxy)-
N,N-diisopropylphosphinamine, DIPEA, DCM; (v) 1. 4-pentynoic acid, DCC, dioxane, 2. Py, 
DMAP (cat). 
Immobilization of the alkyne tether of the 3´-terminal nucleoside (55a) to the 
tetraazido support (45) was carried out by Cu(I) catalyzed 1,3-dipolar 
cycloaddition on using a catalytic amount of CuI and sodium ascorbate in 
dimethylacetamide (DMAc) followed by degassing91, to obtain 56a. The 1-





































































a : R = Bz










d : R = N=CH-NMe2





c : R = N=CH-NMe2
c´ : R = NH2
















mixture of 2:1 (v/v) of dioxane and MeOH. After 1h reaction, the solvent was 
removed by evaporation under reduced pressure. Addition of pyridine neutralized 
any traces of acid sill present in the mixture and precipitation from Et2O gave 
instantly 56b. The white precipitate was isolated and the identity and homogeneity 
of 56b was confirmed by ESI-MS and RPHPLC analysis. 
The applicability of the branched support 56b to the assembly of 5’-ACGUU-3’ 
pentamer was carried out by using 6 equiv. (1.5 eq per free OH group in cluster 
56b) of 5’-O-(1-methoxy-1-methylethyl)-2’-(2-cyanoethyl) 3′-(2-cyanoethyl-N,N-
diisopropylphosphoramidite) building blocks (54a’,b,c’’,d). 4,5-
dicyanoimidazole (6 eq), added as 0.25 M solution in MeCN, was used as an 
activator. Upon 12 h stirring under nitrogen, the standard aqueous iodine oxidation 
solution (I2:H2O:THF:2,6-lutidine 0.22g: 2mL: 4mL: 1mL) was added until the 
dark color remained and the reaction was left for 20min at r.t. The excess of iodine 
was removed by the addition of 1M P(OMe)3 solution in DMF until the dark color 
disappeared. Then the reaction mixture was concentrated to oil, and quantitative 
precipitation of the growing oligonucleotide chain from cold MeOH removed 
small molecular weight reagents and impurities, as shown by RPHPLC studies 
(Figure 1A and 1B, article III). The white precipitate was isolated by filtration over 
celite (acid-washed). Acid-catalyzed methanolysis was then carried out by using 
0.015 M HCl in MeOH/DCM (2:5 v/v), and the acid was neutralized by addition 
of pyridine and the reaction mixture was concentrated to oil. Finally, precipitation 
of the oligonucleotide from cold MeOH and filtration over celite removed 
undesired surplus reagents and impurities. RPHPLC analysis indicated that the 
product was nearly homogenous. Only traces of debenzoylation and removal of 
cyanoethyl from the phosphate groups were observed (Figure 2A and 2B, article 
III). The product was dried under vacuum and ESI-MS confirmed the identity of 
the compound. The coupling cycle was repeated in a similar manner by using the 
phosphoramidite building blocks 54a’,b,c’’,d for the synthesis of the oligomer in 
the sequential order 5’-AdmfCBzGdmfUUBz-3’. Upon completion of the pentamer, 
treatment with TEA followed by ammonolysis and treatment with 1M TBAF in 
THF released the chain from the soluble support and removed all protecting 
groups. The oligomer was then subjected to precipitation from cold EtOH with the 
aid of NaOAc buffer (pH = 5.2) for 1.5h at -20C. Scheme 17 represents the general 
procedure of the oligonucleotide synthesis on using the clustered pentaerythritol 
support (48) and building blocks (54a’,b,c’’,d).The identity of the compounds was 
verified by ESI-MS at different stages of the synthesis (Table 1, article III) and 
final RPHPLC analysis revealed that nearly homogeneous pentamer product had 
been obtained (Figure 3, article III) in high yield (54% overall yield, according to 
























56a : R = C(OMe)Me2








Coupling cycle: 1. Nucleoside phosphoramidite (54a',b,c'',d), 4,5-dicyanoimidazole, MeCN/DMF, N2;
2. I2, H2O, THF, 2,6-lutidine, then P(OMe)3 in DMF
3. Precipitation in MeOH
4. HCl in DCM/MeOH, then Py
5. Precipitation in MeOH
The nuceloside phosphoramidites coupled in the order: 54a' (B = uracil), 54b (B = N2-dimethylaminomethyleneguanine),
54c'' (B = N4-benzoylcytosine), 54d (B = N6-dimethylaminomethyleneadenine).
















Scheme 17. General strategy for the assembly of oligoribonucleotides on using       5’-O-(1-
methoxy-1-methylethyl)-2’-O-(2-cyanoethyl)-protected phosphoramidite building blocks on a 
pentaerythritol-derived soluble support. 
Although the efficiency of the synthesis was demonstrated by the assembly of a 
pentameric ON in good yield and in hundreds of mg scale, one drawback of this 
protocol is the laborious preparation of the 5’-O-(1-methoxy-1-methylethyl)-
protected phosphoramidite building blocks that are not commercially available. 
For the needs of researchers that only occasionally use RNA synthesis and are not 
used to synthesize phosphoramidite building blocks, an alternative platform was 
explored by using the pentaerythritol-derived support and commercially available 
5´-O-(4,4´-dimethoxytriyl)-2´-O-(tert-butyldimethylsilyl)ribonucleo-side 3´-O-
(2-cyanoethyl-N,N-diisopropylphosphoramidite)s as building blocks. 
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3.3.2 Assembly of oligoribonucleotides from 5’-O-(4,4’-dimethoxy-trityl)-2´-
O-(tert-butyldimethylsilyl)-protected building blocks. 
The objective of this study was to develop a general protocol for the synthesis of 
short oligoribonucleotides in solution on using the branched pentaerythritol-
derived soluble support and commercially available 5´-O-(4,4´-dimethoxytrityl)-
2´-O-(tert-butyldimethylsilyl)-3´-O-(2-cyanoethyl-N,N-diisopropylphosphorami-
dite) building blocks (U, ABz, Gibu and CAc). As stated previously, the use of more 
hydrophobic 2’-O-TBDMS groups do not allow precipitation of the growing 
oligonucleotide from MeOH and, hence, one precipitation from water after the 
oxidation step and one chromatographic purification upon the 5’-detritylation were 
needed in each synthetic cycle in order to remove contaminants from the reaction 
mixture.  
The preparation of the 3’-terminal alkyne derivative of uridine was similar to that 
reported above except that 2´-O-(tert-butyldimethylsilyl) protection was used 
instead of 2´-O-(2-cyanoethyl). The synthesis started by selective silylation of the  
5’-OH and 3’-OH groups of uridine (57) with di-tert-butylsilanediyl 
bis(trisfluoromethanesulfonate) in anhydrous DMF92 (Scheme 18). The 2’-
hydroxy group was then silylated with TBDMSCl in the presence of imidazole in 
DMF to afford 58. The amino group of the base moiety was benzoylated by 
treatment with BzCl in the presence of Na2CO3, yielding 59. To prevent N3 
acylation during the introduction of the ω-alkynoyl linker to the 3´O, N3 was 
benzoylated before removal of the di-tert-butylsilanediyl group, which was 
accomplished by treatment with HF-Py in pyridine to afford (60). The 5´-O-DMTr  
protection was then introduced with DMTrCl in pyridine to obtain 61. Finally the 
3´-OH group of the nucleoside (61) was converted to a 3´-O-(pent-4-ynoyl) 
derivative by acylation with pent-4-ynoic anhydride prepared in situ, to afford 62, 
as shown in Scheme 18. 
 
Scheme 18. Synthesis of fully protected uridine bearing a 3’-O-(pent-4-ynol) linker. Reagents 
and conditions: (i) t-Bu2Si(OTf)2 , DMF; (ii) t-BuMe2SiCl, Im, DMF; (iii) BzCl, Na2CO3; (iv) 
HF-Py, O oC, DCM; (v) DMTrCl, Py; (vi) 1. 4-pentynoic acid, DCC, dioxane, 2. Py, DMAP (cat). 
The alkyne functionalized nucleoside (62) was conjugated to the tetrakis-O-(4-







































58 R1 = H
59 R1 = Bz
R1
60 R2 = H
61 R2 = DMTr
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cycloaddition using a catalytic amount of CuI and sodium ascorbate in 
dimethylacetamide (DMAc) followed by degassing91, to obtain 63a. The 
nucleoside bearing support (63a) was subjected to acid-catalyzed methanolysis 
with HCl (5 mM) in a mixture of DCM/MeOH 1:1 (v/v) and the DMTrOMe formed 
was removed by chromatographic purification to afford 63b. The identity and 
homogeneity of the compound was confirmed by ESI-MS and RPHPLC (Figure 
1, article IV), respectively. 
A pentameric 5’-AGCUU-3’ oligoribonucleotide was then assembled to 
demonstrate the applicability of the method (Scheme 19). Couplings were 
performed on using 1.5 equiv. of commercially available building blocks (64a-d) 
per each free 5’-hydroxyl group on the support and an equal amount of 4,5-
dicyanoimidazole as the activator (added as 0.25 M solution in MeCN). After 12h 
reaction, the phosphite triester was oxidized to phosphate triester by 25 min 
treatment with an aqueous iodine oxidation, as described above. Excess of iodine 
was quenched with trimethylphosphite. Since precipitation from MeOH was not 
possible, owing to the higher hydrophobicity of the TBDMS group compared to 
the 2-cyanoethyl group, the system was readapted and quantitative precipitation 
from water was performed for partial removal of reagents, as shown in RPHPLC 
analysis (Figure 2A and 2B, article IV). Although the byproducts derived from 
unreacted building blocks were only partly removed by this method, this did not 
prevent continuation of the coupling cycle by the detritylation step. The white 
precipitate was filtered, isolated and subjected to detritylation by treatment with 
HCl (5 mM) in a mixture of DCM/MeOH 5:2 (v/v). Pyridine was added to the 
solution to neutralize the acid and the mixture was concentrated to oil. The support 
was then purified by column chromatography by using a 1-8% gradient of MeOH 
in DCM. The identity and homogeneity of the compound was confirmed by ESI-
MS (Table 1, article IV) and RPHPLC (Figure 3, article IV), respectively. The 
coupling cycle was repeated in a similar manner by using phosphoramidite 
building blocks 64a-d for the synthesis of the oligomer to obtain 5’-
ABzGiBuCAcUUBz-3’. During the synthesis, traces of debenzoylation and removal 
of the 2-cyanoethyl groups from the phosphate moiety occurred (Figure 1B, article 
IV). Upon completion of the pentamer, treatment with TEA followed by 
concentrated aqueous ammonia and 1:1 (v/v) mixture of dry DMSO and (HF)3Et3N 
released the oligonucleotide from the support and cleaved all protecting groups. 
The oligomer was then subjected to precipitation from cold EtOH with NaOAc 
buffer (pH = 5.2) for 1.5h at -20C. Scheme 19 represents the general procedure of 
the oligonucleotide synthesis on using the clustered pentaerythritol support (63b) 
and commercially available building blocks (64a-d).The identity of the 
compounds was confirmed by ESI-MS at any stage of the synthesis (Table 1, 
article IV) and final RPHPLC analysis verified formation of the nearly 
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homogeneous pentamer (Figure 4, article IV) in high yield (46% overall yield 
according to UV spectroscopic analysis compared to support 63b).  
Scheme 19. General strategy for the assembly of oligoribonucleotides on using 5’-O-(4,4´-
dimethoxytrityl)-2´-O-(tert-butyldimethylsilyl)-protected phosphor-amidite building blocks on a 
pentaerythritol-derived soluble support. 
Although the overall yield of the pentamer was slightly lower than the one  
obtained on using 5’-O-(1-methoxy-1-methylethyl)-2’-O-(2-cyanoethyl)-
protected phosphoramidite building blocks (43% vs. 54%), the protocol is still 
workable in cases where researchers want to use only commercially available 





The objective of the MEMTIDE project was to develop a scalable solution phase 
strategy for oligonucleotide synthesis that would offer an efficient and versatile 
platform for the emerging OSN technique. The general idea was to assemble the 
oligonucleotide attached to a soluble support and perform the separation of the 
growing oligonucleotide from excess reagents and impurities after each coupling 
by nanofiltration in organic solvent (OSN). Initial attempts using acetylated and 
methylated CDs and also the pentaerythritol soluble support in the laboratory of 
Prof A. Livingstone at Imperial College London have given engouraging results 
when the membrane filtration technique has been applied. However, significant 
optimization of chemistry and membranes has still to be done to increase the yield. 
While these approaches will hopefully lead to novel industrial technology, the 
approaches described in the present theses are believed to be useful in normal 
organic chemistry laboratories for preparation of oligonucleotides of limited length 
in the scale of hundreds of milligrams.  
In the Results chapter, a description of various novel solution phase synthesis 
strategies has been presented. The syntheses of short oligonucleotides on 
acetylated and methylated β-CDs, and, in particular, on the pentaerythritol-derived 
soluble support have provided strong evidence that solution phase synthesis may 
well be applied in cases where large amounts of short ONs are needed without the 
need of any special infrastructure. For instance, we have demonstrated that 
hundreds of mg quantities may be easily produced in the laboratory. In addition, 
these approaches neatly have provided similar overall yields compared to those 
previously reported protocols on using different soluble supports, such as PEG 
(Polyethylene-glycol),61,62,63,64,65,66,67 (adaman-1-yl)acetyl68 or succinyl-tethered-
1-ethyl-3-methylimidazolium tetrafluoroborate69. Furthermore, apart from 
extractive work-up, diafiltration and precipitation, we have also established 
chromatography as a tool for the purification of the growing oligonucleotide while 
using the acetylated and methylated β-CDs. Although the commonly used 
precipitation and extraction techniques essentially exhibit potential for the large-
scale purification processes, none of them have yet been applied for the synthesis 
of ONs with commercial purposes. Since all these protocols commented above are 
operated entirely in solution phase, the high reaction rates and the large reaction 
volumes should not be a problem. 
As regards oligonucleotide assembly on a soluble support, numerous protocols 
have been reported for the preparation of oligodeoxyribonucleotides, but none of 
these attempts have so far been applied to the synthesis of oligoribonucleotides. 
60  Discussion 
 
For that reason, upon completion of the DNA studies, we decided to apply two 
different protocols on using the pentaerythritol-derived soluble support for the 
assembly of RNA. As mentioned in the Results chapter, in the first case the use of 
5’-O-(1-methoxy-1-methylethyl)-2’-O-(2-cyanoethyl)-protected phosphor-
amidite building blocks gave good results on using the precipitation technique for 
the purification of the growing oligonucleotide. The second protocol utilized 
commercially available 5’-O-(4,4´-dimethoxytrityl)-2´-O-(tert-butyldimethyl-
silyl)-protected phosphoramidite building blocks and chromatographic 
purification on the same soluble support. In both cases, the simplicity and 
reproducibility of these protocols were suitable to ensure a nearly homogeneous 
pentameric product. Nevertheless, the methodology has not yet been applied for 
the synthesis of longer oligonucleotides, which could be affected due to some 
solubility problems of the soluble support upon each elongation of the chain 
assembly. 
Although the current state-of-the-art platform is the well-known solid-phase 
oligonucleotide synthesis, it seems worthwhile to use a combination of both SPS 
and LPS to develop a scalable manufacture platform that permit the synthesis of 
oligonucleotide-based drugs in multi-Kg or ton scales for chemotherapeutical 
purposes in the pharmaceutical industry. Since the SPS uses a completely machine-
automated procedure and avoids any human error during the synthesis, the 
platform could be combined with the LPS for a cost-effective scale-up 
manufacture process. Although the feasibility for a large scale process design is 
still difficult but not impossible, the optimization of the chemistry and new 




General synthesis and characterization of the compounds 
The synthetic methods mentioned in this thesis are reported in the original 
publications (I-IV). The characterization of compounds was carried out by NMR 
(1D and 2D), HRMS and RP HPLC techniques. NMR spectra were recorded on a 
Bruker Avence 500 MHz or 400 MHz at 25 °C, in which chemical shifts are given 
in ppm and are referred to internal TMS (for 1H and 13C NMR) and to external 
orthophosphoric acid (for 31P NMR). High resolution mass spectra (HRMS) were 
recorded on a Bruker Daltonics MicrOTOF-Q spectrometer using ESI ionization. 
RP HPLC analyses were performed on an analytical Thermo ODS Hypersil C18 
(250 × 4.6 mm, 5μm) column using UV detection at 260 nm. In addition, reactions 
were monitored by TLC (Merck, Silica gel 60 F254), using short wavelength UV 
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